Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The general aim of the trial is to determine the safety, tolerability and pharmacologic
profile of single escalating doses of AbGn-168 administered subcutaneously or intravenously
to patients with chronic plaque psoriasis